Article

FDA Approves Herceptin Biosimilar for Breast Cancer Treatment

The FDA has approved Herzuma (trastuzumab-pkrb) (Herzuma) as a biosimilar to Herceptin (trastuzumab, Genentech). Trastuzumab-pkrb is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer.

The FDA has approved Herzuma (trastuzumab-pkrb) (Herzuma) as a biosimilar to Herceptin (trastuzumab, Genentech). Trastuzumab-pkrb is a HER2/neu receptor antagonist indicated for the treatment of HER2-overexpressing breast cancer.

Common expected adverse effects of Herzuma include headache, diarrhea, nausea, chills, fever, infection, congestive heart failure, insomnia, cough and rash. Serious expected adverse effects of Herzuma include worsening of chemotherapy-induced neutropenia.

Like Herceptin, the labeling for Herzuma contains a Boxed Warning to alert health care professionals and patients about increased risks of cardiomyopathy, infusion reactions, pulmonary toxicity and embryo-fetal toxicity.

This article originally appeared on Specialty Pharmacy Times as "FDA Approves Herceptin Biosimilar Treatment of HER2-overexpressing Breast Cancer."

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of a woman wearing a headband and glasses
Image of doctor.
Image of woman.
Image of Doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Image of man with grey hair.
Related Content
Dr. Rugo has led key breast cancer therapy trials and exudes a passion for serving patients.
April 18th 2025

Renowned Breast Cancer Physician-Scientist Dr. Hope S. Rugo to Lead City of Hope’s Women’s Cancers Program

City of Hope
Dr. Rugo has led key breast cancer therapy trials and exudes a passion for serving patients.
FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment
February 5th 2024

FDA, Cancer Vaccine Updates and a Misguiding of Breast Cancer Treatment

Alex Biese Brielle Benyon
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Illustration of women.
April 16th 2025

Sometimes, Distractions Help During Breast Cancer

Laura Yeager
After a mammogram and breast cancer scare, a Broadway show provided a welcome distraction and joy, reminding me of life's beauty.
Cancer Horizons podcast logo
December 12th 2023

Conference Highlights from SABCS

Alex Biese Brielle Benyon
CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of legs.
April 6th 2025

Raising Awareness for Lymphedema Following a Cancer Diagnosis

Ryan Scott
Dr. Sheri Yolanda Prentiss explores the challenges patients face in accessing lymphedema compression garments following cancer treatment.
Image of woman.
April 4th 2025

The Miniature Zen Garden: A Useful Tool for Those Dealing with Cancer

Laura Yeager
I tried using a Zen garden that helped me meditate and relax while dealing with the challenges of cancer, and it really works.